Identification

Name
Flupentixol
Accession Number
DB00875  (APRD00388)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States.

Structure
Thumb
Synonyms
  • Flupenthixol
  • Flupenthixole
  • Flupentixol
  • Flupentixolo
  • Flupentixolum
External IDs
FX 703 / LC 44 / LC-44 / LU 5-110 / N 7009 / N-7009
Product Ingredients
IngredientUNIICASInChI Key
Flupentixol decanoate3B2FE28C1W30909-51-4UIKWDDSLMBHIFT-UHFFFAOYSA-N
Flupentixol dihydrochloride96L0Z069N151529-01-2IOVDQEIIMOZNNA-MHKBYHAFSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluanxol 0.5mg - TabTablet0.5 mgOralLundbeck Inc.1995-12-31Not applicableCanada
Fluanxol 3mg - TabTablet3 mgOralLundbeck Inc.1995-12-31Not applicableCanada
Fluanxol Depot 10%- Liq Im 100mg/mlSolution100 mgIntramuscularLundbeck Inc.1995-12-31Not applicableCanada
Fluanxol Depot 2% -liq Im 20mg/mlSolution20 mgIntramuscularLundbeck Inc.1995-12-31Not applicableCanada
Fluanxol Depot Inj 100mg/mlLiquid100 mgIntramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Depot Inj 20mg/mlLiquid20 mgIntramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Tab 0.5mgTablet0.5 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Fluanxol Tab 3mgTablet3 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Flupentixol Decanoate Injection BPSolution20 mgIntramuscularSandoz Canada IncorporatedNot applicableNot applicableCanada
Flupentixol Decanoate Injection BPSolution100 mgIntramuscularSandoz Canada Incorporated2009-08-27Not applicableCanada
International/Other Brands
Depixol (Lundbeck A/S) / Fluanxol (Lundbeck A/S) / Jexit (Johnson)
Categories
UNII
FA0UYH6QUO
CAS number
2709-56-0
Weight
Average: 434.52
Monoisotopic: 434.163969096
Chemical Formula
C23H25F3N2OS
InChI Key
NJMYODHXAKYRHW-DVZOWYKESA-N
InChI
InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[(9Z)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F

Pharmacology

Indication

For use in the treatment of schizophrenia and depression

Structured Indications
Pharmacodynamics

Flupenthixol is an anxiolytic, antidepressive agent and a mood stabilizer. It inhibits the central monoamine receptors, particularly the dopamine D1 and D2 receptors. Therefore, it increases the amount of serotonin and noradrenaline that control mood and thinking, and improves mood.

Mechanism of action

Flupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption

Fairly slow and incomplete after oral administration

Volume of distribution
Not Available
Protein binding

Highly bound to plasma proteins (>95%)

Metabolism

Mainly hepatic

Route of elimination
Not Available
Half life

19 to 39 hours

Clearance
Not Available
Toxicity

LD50=300 mk/kg (Oral in mice); LD50=791 mg/kg (Oral in rats); LD50=87 mk/kg (IV in mice); LD50=37 mg/kg (IV in rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFlupentixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFlupentixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Flupentixol.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flupentixol.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Flupentixol.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Flupentixol.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Flupentixol.Approved
AmperozideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amperozide.Experimental
AmphetamineFlupentixol may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Flupentixol.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Flupentixol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azaperone.Investigational, Vet Approved
AzelastineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Flupentixol.Approved
BenperidolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzocaine.Approved
BenzphetamineFlupentixol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzyl alcohol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Flupentixol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bupivacaine.Approved, Investigational
BuprenorphineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Flupentixol.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flupentixol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Flupentixol.Approved
CanertinibThe risk or severity of adverse effects can be increased when Flupentixol is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flupentixol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.Approved
CeritinibCeritinib may increase the QTc-prolonging activities of Flupentixol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flupentixol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorphenamine.Approved
ChlorphentermineFlupentixol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flupentixol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Flupentixol.Approved, Investigational, Withdrawn
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
ClemastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flupentixol.Approved
CocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Flupentixol.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Flupentixol.Approved
CyclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Flupentixol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Flupentixol.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Flupentixol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Flupentixol.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineFlupentixol may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Flupentixol.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flupentixol.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diethyl ether.Experimental
DiethylpropionFlupentixol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flupentixol.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Flupentixol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenoxylate.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Flupentixol.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dixyrazine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Flupentixol.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Flupentixol.Approved
DomperidoneThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Doramectin.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Flupentixol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Flupentixol.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Flupentixol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.Approved
DyclonineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Flupentixol.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Flupentixol.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Flupentixol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Flupentixol.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol.Approved
EthanolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Flupentixol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Flupentixol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Flupentixol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Flupentixol.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Flupentixol.Approved, Vet Approved
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Flupentixol.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Flupentixol.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin Enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Flupentixol.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Flupentixol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
GepefrineFlupentixol may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Flupentixol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flupentixol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Flupentixol.Approved
HydrocodoneFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.Approved, Illicit
HydroxyamphetamineFlupentixol may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Flupentixol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Flupentixol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Flupentixol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Flupentixol.Approved
IndiplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indiplon.Investigational
Iofetamine I-123Flupentixol may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Flupentixol.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Flupentixol.Approved
KetamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketobemidone.Approved, Investigational
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Flupentixol.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Flupentixol.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Flupentixol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flupentixol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Flupentixol.Approved, Investigational
LisdexamfetamineFlupentixol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Flupentixol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lofentanil.Illicit
LopinavirThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flupentixol.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Flupentixol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flupentixol.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Flupentixol.Approved
MebicarThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Flupentixol.Approved
MelatoninThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melperone.Approved, Investigational
MephedroneFlupentixol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFlupentixol may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Meptazinol.Experimental
MequitazineFlupentixol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flupentixol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineFlupentixol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flupentixol.Approved
MethotrimeprazineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineFlupentixol may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Flupentixol.Approved
MetyrosineFlupentixol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flupentixol.Approved, Illicit
MidomafetamineFlupentixol may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Flupentixol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Flupentixol.Approved
MirtazapineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAFlupentixol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Flupentixol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flupentixol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Flupentixol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Flupentixol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Flupentixol.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Flupentixol.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Flupentixol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Opium.Approved, Illicit
OrphenadrineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flupentixol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ParaldehydeFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Flupentixol.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Flupentixol.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flupentixol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
PerazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Flupentixol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flupentixol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.Approved
PhenibutThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenoxyethanol.Approved
PhentermineFlupentixol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Vet Approved
PramipexoleFlupentixol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flupentixol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Flupentixol.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Flupentixol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flupentixol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Flupentixol.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Flupentixol.Approved
PropanididThe risk or severity of adverse effects can be increased when Flupentixol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Propoxycaine.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Flupentixol.Approved
PSD502The risk or severity of adverse effects can be increased when Flupentixol is combined with PSD502.Investigational
PseudoephedrineFlupentixol may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam.Approved, Illicit
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Flupentixol.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Quinidine.Approved
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Flupentixol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Flupentixol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flupentixol.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Flupentixol.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Flupentixol.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ritanserin.Investigational
RitobegronFlupentixol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Flupentixol.Approved
RomifidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Romifidine.Vet Approved
RopiniroleFlupentixol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ropivacaine.Approved
RotigotineFlupentixol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flupentixol.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Flupentixol.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Flupentixol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Flupentixol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Flupentixol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Flupentixol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Flupentixol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
SuvorexantFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Flupentixol.Approved
TandospironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Flupentixol.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Flupentixol.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Flupentixol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flupentixol.Approved
TetracaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrodotoxin.Investigational
ThalidomideFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flupentixol.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Flupentixol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tilidine.Experimental
TizanidineTizanidine may increase the QTc-prolonging activities of Flupentixol.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Flupentixol.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Flupentixol.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flupentixol.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Flupentixol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Flupentixol is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Flupentixol.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Flupentixol.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Flupentixol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Flupentixol.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vinyl ether.Experimental
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Flupentixol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Flupentixol.Approved, Investigational
ZolpidemFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Smith Kline & French Laboratories; British Patent 925,538; May 8, 1963. Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline & French Laboratories.

General References
Not Available
External Links
KEGG Drug
D01044
KEGG Compound
C11191
PubChem Compound
5281881
PubChem Substance
46507816
ChemSpider
4445173
BindingDB
79172
ChEBI
10454
ChEMBL
CHEMBL54661
Therapeutic Targets Database
DAP000026
PharmGKB
PA10268
IUPHAR
968
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Flupenthixol
ATC Codes
N05AF01 — Flupentixol
AHFS Codes
  • 28:16.08.32 — Thioxanthenes

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBioequivalence Study in Healthy Subjects1
1Unknown StatusTreatmentCocaine-Related Disorders1
2CompletedTreatmentCocaine-Related Disorders2
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentSubstance-Related Disorders1
3RecruitingTreatmentGlobus1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4CompletedTreatmentCompliance / Depression / Indigestion1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral0.5 mg
TabletOral3 mg
SolutionIntramuscular100 mg
SolutionIntramuscular20 mg
LiquidIntramuscular100 mg
LiquidIntramuscular20 mg
Prices
Unit descriptionCostUnit
Fluanxol Depot 100 mg/ml39.79USD ml
Fluanxol Depot 20 mg/ml7.96USD ml
Fluanxol 3 mg Tablet0.59USD tablet
Fluanxol 0.5 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility0.000346 mg/mlNot Available
logP4.51HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00399 mg/mLALOGPS
logP4.56ALOGPS
logP4.5ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity128.17 m3·mol-1ChemAxon
Polarizability44.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9825
Blood Brain Barrier+0.9778
Caco-2 permeable-0.5438
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.92
P-glycoprotein inhibitor IIInhibitor0.859
Renal organic cation transporterInhibitor0.5065
CYP450 2C9 substrateNon-substrate0.8084
CYP450 2D6 substrateSubstrate0.804
CYP450 3A4 substrateNon-substrate0.6921
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.828
CarcinogenicityNon-carcinogens0.8985
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8385 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6624
hERG inhibition (predictor II)Inhibitor0.7962
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiopyrans
Sub Class
1-benzothiopyrans
Direct Parent
Thioxanthenes
Alternative Parents
Diarylthioethers / N-alkylpiperazines / Benzenoids / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives
show 1 more
Substituents
Thioxanthene / Diarylthioether / Aryl thioether / N-alkylpiperazine / 1,4-diazinane / Piperazine / Benzenoid / 1,2-aminoalcohol / Tertiary aliphatic amine / Tertiary amine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
thioxanthenes (CHEBI:10454)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L: Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74. [PubMed:6149133]
  4. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321]
  5. Huettl P, Gerhardt GA, Browning MD, Masserano JM: Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells. J Pharmacol Exp Ther. 1991 May;257(2):567-74. [PubMed:1674528]
  6. Nilsson CL, Ekman A, Hellstrand M, Eriksson E: Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology. 1996 Jul;15(1):53-61. [PubMed:8797192]
  7. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172]
Details
3. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405]
  4. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Pyridoxal phosphate binding
Specific Function
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name
DDC
Uniprot ID
P20711
Uniprot Name
Aromatic-L-amino-acid decarboxylase
Molecular Weight
53925.815 Da
References
  1. Zhu MY, Juorio AV, Paterson IA, Boulton AA: Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol. 1994 May;112(1):23-30. [PubMed:7913379]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615]
  2. Dey S, Hafkemeyer P, Pastan I, Gottesman MM: A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry. 1999 May 18;38(20):6630-9. [PubMed:10350482]
  3. Hafkemeyer P, Licht T, Pastan I, Gottesman MM: Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther. 2000 Mar 1;11(4):555-65. [PubMed:10724034]
  4. Yang JM, Vassil A, Hait WN: Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol. 2002 Mar 1;63(5):959-66. [PubMed:11911848]
  5. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990 Mar 15;50(6):1748-56. [PubMed:1968358]
  6. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res. 1991 Jan 1;51(1):67-72. [PubMed:1988108]

Drug created on June 13, 2005 07:24 / Updated on November 22, 2017 12:31